Is Axsome Therapeutics, Inc. (AXSM) a Buy, Sell, or Hold?
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$235.26 USD
$6.98 (3.06%)
- Volume
- 482.76K
- Average Volume
- 923.51K
- Market Capitalization
- $12.11B
- P/E Ratio
- -63.07
- Dividend Yield
- 0.00%
- Price Target
- $259.50
- Year High
- $260.19
- Year Low
- $96.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.39
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Herriot Tabuteau |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AXSM |
| CUSIP | 05464T104 |
| CIK | 0001579428 |
| Web | https://www.axsome.com |
| Phone | 212 332 3241 |
| Currency | USD |
| Employees | 1220 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 4.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.39 |
| Quick Ratio | 1.32 |
| Cash Ratio | 0.69 |
Sales & Book Value
| Annual Sales | $638.5M |
| Price / Sales | 17.09 |
| Cash Flow | -1.39 |
| Price / Cash Flow | -170.53 |
| Price / Book | 220.66 |
Price Target and Rating
| Average Stock Price Forecast | $259.50 |
| High Stock Price Forecast | $380.00 |
| Low Stock Price Forecast | $200.00 |
| Forecast Upside/Downside | -9.34% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 26 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.68 |
| Trailing P/E Ratio | -63.07 |
| PEG Ratio | -1.41 |
| P/E Growth | -1.41 |
| Net Income | $-183.17M |
| Net Margin | -26.59% |
| Pretax Margin | -26.66% |
| Return on Equity | -260.01% |
| Return on Assets | -26.39% |
Financials Score
| AltmanZ Score | 8.71 |
| Piotroski Score | 4.00 |
| Working Capital | 172M |
| Total Assets | 713.61M |
| Ebit | -181.24M |
| Market Cap | 12.03B |
| Total Liabilities | 659.02M |
Poll Results
About Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a s ... elective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
2026-07-14 07:00:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2026 on Monday, August 10, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
3 Under-the-Radar Stocks to Buy and Hold
2026-07-10 14:30:00
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Better Growth Buy: Axsome vs Revolution Medicines
2026-07-09 03:55:00
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
2026-07-08 12:20:16
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
2026-07-07 07:00:00
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-2 Phase 3 trial evaluating solriamfetol as a treatment for children with attention deficit hyperactivity disorder (ADHD). FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol in children aged 6 to less than 12 years with ADHD.
2026-07-06 18:10:00
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
2026-07-02 08:05:00
Axsome specializes in central nervous system disorders, including depression, migraine, and fibromyalgia. Axsome's Auvelity recently won approval to treat agitation associated with Alzheimer's disease.
Why Axsome Stock Has Doubled In Nine Months
2026-07-01 12:10:42
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inbox, subscribe here.
Frequently Asked Questions
-
What is the current Axsome Therapeutics, Inc. (AXSM) stock price?
-
Axsome Therapeutics, Inc.(NASDAQ:AXSM) stock price is $235.26 in the last trading session. During the trading session, AXSM stock reached the peak price of $260.19 while $96.09 was the lowest point it dropped to. The percentage change in AXSM stock occurred in the recent session was 3.06% while the dollar amount for the price change in AXSM stock was $6.98.
-
AXSM's industry and sector of operation?
-
The NASDAQ listed AXSM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AXSM?
-
Ari Maizel | Chief Commercial Officer
Hunter Murdock | General Counsel & Secretary
Nick Pizzie | Chief Financial Officer
Darren Opland | Director of Corporate Communications
Mark L. Jacobson | Chief Operating Officer -
How many employees does AXSM have?
-
Number of AXSM employees currently stands at 1220. AXSM operates from 22 Cortlandt Street, New York City, NY 10007, US.
-
Link for AXSM official website?
-
Official Website of AXSM is: https://www.axsome.com
-
How do I contact AXSM?
-
AXSM could be contacted at phone #212 332 3241 and can also be accessed through its website. AXSM operates from 22 Cortlandt Street, New York City, NY 10007, US.
-
How many shares of AXSM are traded daily?
-
The average number of AXSM shares traded daily for last 3 months was 923.51K.
-
What is the market cap of AXSM currently?
-
The market value of AXSM currently stands at $12.11B with its latest stock price at $235.26